BioSpace News Archive

INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”) today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period.

Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, announced the launch of its new pipeline company, Telos Biotech.

OmicsEdge has proudly announced the presentation of their revolutionary new ancestry inference method at the European Society of Human Genetics meeting held in Glasgow, Scotland.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance.

AVEO Oncology, an LG Chem company, (“AVEO”), announced today that it has completed enrollment in the pivotal Phase 3 TiNivo-2 study in patients with advanced relapsed or refractory renal cell carcinoma (RCC) following prior immunotherapy exposure.

Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) (“Dermata” or the “Company”) today announced that following the Company’s receipt of FDA responses to its End of Phase 2 meeting package, the Company’s DMT310 Phase 3 clinical development program for the once-weekly topical treatment of patients with moderate-to-severe acne is on track to begin in the second half of 2023.

IAVI announced today that the first participants have been vaccinated with a Sudan virus (SUDV) vaccine candidate in a first-in-human Phase I clinical trial in the U.S.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the publication of a new paper in Frontiers in Aging, a peer-reviewed journal focused on age-related scientific research.

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, announced that the ERIC Retrieval Device is now commercially available in the United States for ischemic stroke treatment.

Powered by a commitment to accelerating bold, emerging science, the Parker Institute for Cancer Immunotherapy continues to invest in the next generation of scientific leaders and their ambitious ideas for curative cancer treatments.